{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:46:40Z","timestamp":1782913600506,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Managing persistent soft tissue residual disease in high-risk neuroblastoma (HR-NB) remains a clinical challenge, particularly when conventional response assessments suggest remission but residual lesions persist. Determining whether such lesions represent inactive treatment-related changes or viable tumor has important implications for subsequent management. We report a 4-year-and-11-month-old girl with HR-NB who received multimodal therapy, including induction chemotherapy, surgery, radiotherapy, autologous stem cell transplantation, and seven cycles of dinutuximab beta-based immunotherapy. Following treatment, standard evaluations demonstrated complete bone marrow clearance and a ^123I-MIBG Curie score of 0, suggesting an excellent systemic response. However, a persistent paravertebral residual lesion remained detectable on imaging. Notably, ^68Ga-DOTA-NOC PET\/CT demonstrated persistent tracer uptake despite negative ^123I-MIBG findings, creating an imaging discordance that raised concern for residual viable disease. Subsequent \u201cthird-look\u201d surgical resection confirmed viable neuroblastoma within the lesion. Pathological examination revealed a markedly increased Ki-67 labeling index compared with the post-induction specimen (50% versus 8%), indicating persistent proliferative activity and suggesting biological heterogeneity within the residual lesion. This case highlights the diagnostic and therapeutic challenges posed by persistent soft tissue residual lesions after immunotherapy. The discordance between ^123I-MIBG and ^68Ga-DOTA-NOC imaging suggests that conventional imaging alone may not fully characterize selected residual lesions. In patients with persistent masses and discordant imaging findings, multimodal functional imaging may provide complementary information to guide clinical decision-making. The favorable outcome observed in this patient, who remains in sustained remission following surgical resection without additional antitumor therapy, supports consideration of an integrated management strategy combining multimodal imaging assessment and appropriately timed surgical intervention for selected cases of persistent residual disease.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1867416","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:05:03Z","timestamp":1782911103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of persistent soft tissue residuals exhibiting an imaging paradox (^123I-MIBG-negative\/^68Ga-DOTA-NOC-positive) in high-risk neuroblastoma following immunotherapy: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Si-jia","family":"He","sequence":"first","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-qian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1186\/s12885-024-13044-5","article-title":"Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12016","article-title":"Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma","volume":"40","author":"He","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34693","article-title":"Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy","volume":"153","author":"Kushner","year":"2023","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1106597","article-title":"Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease","volume":"12","author":"Fong","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01155-3","article-title":"Efficacy and safety of anti-GD2 immunotherapy with dinutuximab beta in the treatment of relapsed\/refractory high-risk neuroblastoma","volume":"20","author":"Wieczorek","year":"2025","journal-title":"Target Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00259-024-06622-z","article-title":"Head-to-head comparison between [(68)Ga]Ga-DOTA-NOC and [(18)F]DOPA PET\/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas","volume":"51","author":"He","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104541","article-title":"(131)I-mIBG therapy in relapsed\/refractory neuroblastoma: an old bridge to the future","volume":"10","author":"De Ioris","year":"2025","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71332","article-title":"Histologic response to induction chemotherapy in high-risk neuroblastoma","volume":"14","author":"Pomaville","year":"2025","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12591","article-title":"Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00427-5","article-title":"Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes","volume":"3","author":"Sengupta","year":"2022","journal-title":"Nat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70008","article-title":"Antibody-dependent cellular cytotoxicity of iPS cell-derived natural killer T cells by anti-GD2 mAb for neuroblastoma","volume":"116","author":"Nishimura","year":"2025","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9570","DOI":"10.1038\/s41467-024-53776-3","article-title":"Neuroblastoma plasticity during metastatic progression stems from the dynamics of an early sympathetic transcriptomic trajectory","volume":"15","author":"Villalard","year":"2024","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.3390\/ijms26104722","article-title":"Targeting pathways in neuroblastoma: Advances in treatment strategies and clinical outcomes","volume":"26","author":"Benchia","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382931","article-title":"Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells","volume":"15","author":"Di Matteo","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1038\/s41467-025-63979-x","article-title":"RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity","volume":"16","author":"Singh","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00468-5","article-title":"Adverse reaction reporting for naxitamab in Chinese expanded access treatment for relapsed\/refractory high-risk neuroblastoma at the Children's Hospital of Fudan University","volume":"12","author":"Qian","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2525739","article-title":"NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy","volume":"17","author":"Lyu","year":"2025","journal-title":"Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8431","DOI":"10.3390\/ijms26178431","article-title":"Ganglioside profiling uncovers distinct patterns in high-risk neuroblastoma","volume":"26","author":"Paret","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70165","article-title":"A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): a report from the Children's Oncology Group","volume":"132","author":"Desai","year":"2026","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-025-04010-6","article-title":"GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout","volume":"74","author":"Junemann","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29551","article-title":"Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: a multicentre international study","volume":"69","author":"Cortes","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02158-6","article-title":"Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring","volume":"57","author":"Yu","year":"2025","journal-title":"Nat Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1867416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:05:04Z","timestamp":1782911104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1867416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1867416"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1867416","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1867416"}}